Ambrx to price its IPO of 5.4 million shares between $12.00 and $14.00

Stifel and Wells Fargo Securities to be bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., June 9 – Ambrx, Inc. will sell 5.4 million common shares in its initial public offering with a 30-day greenshoe option of 810,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced May 2.

The shares will be sold at a price expected to fall between $12.00 and $14.00 per share.

Stifel and Wells Fargo Securities are the joint bookrunning managers. Canaccord Genuity, Needham & Co. and Roth Capital Partners are the co-managers.

Proceeds will be used for clinical trials, research and development, working capital and general corporate purposes.

The biotechnology company is based in La Jolla, Calif. The company intends to list its common stock on the Nasdaq under the symbol “AMBX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.